No Data
Shanghai Yizhong: Announcement on the 2024 Annual Results Report of Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong Pharmaceutical Co., Ltd. 2024 Annual Results Express Announcement
Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Shanghai Yizhong Pharmaceutical Co., Ltd. 2024 Annual Results Forecast Announcement
Shanghai Yizhong (688091.SH): The net income for 2024 is expected to decrease by 93.81% to 95.05%.
On January 17, Gelonghui reported that Shanghai Yizhong (688091.SH) announced its performance forecast for 2024, expecting to achieve a net income attributable to the owners of the parent company of 8 million to 10 million yuan; a decrease of 93.81% to 95.05% year-on-year. The company expects the net income attributable to the owners of the parent company, excluding non-recurring gains and losses, to be 4 million to 6 million yuan; a year-on-year decrease of 96.28% to 97.52%.
Shanghai Yizhong (688091.SH): has actually repurchased 0.6168% of the shares.
Gelonghui, December 26th丨Shanghai Yizhong (688091.SH) announced that as of the date of this announcement, the company's share repurchase period has expired. The company has actually repurchased 1,274,307 shares, accounting for 0.6168% of the company's total share capital of 206,589,240 shares; the actual amount repurchased is 37,240,964.92 yuan (excluding transaction fees); the highest price for repurchase transactions was 48.00 yuan/share, and the lowest price was 25.54 yuan/share.
